How much does CALQUENCE (Acalabrutinib Capsules) Cost& price without insurance in China?
CALQUENCE® is the commercial brand name of Acalabrutinib Capsules, a highly selective, irreversible second-generation Bruton tyrosine kinase (BTK) inhibitor developed by AstraZeneca. It exerts anti-tumor activity by covalently binding to BTK, thereby inhibiting B-cell receptor signaling and blocking the proliferation and survival of malignant B-cells.
Main Indications
Treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL);
Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Common Side Effects
Common adverse reactions: Headache, diarrhea, fatigue, myalgia, nausea, bruising, rash, abdominal pain, constipation, and vomiting.
Laboratory abnormalities: Decreased hemoglobin, decreased neutrophil count, decreased platelet count, and elevated transaminases.
Severe but manageable risks: Hemorrhagic events (including serious bleeding), infections (including pneumonia), atrial fibrillation/flutter, and secondary malignancies.
Approval Status in China
CALQUENCE® (Acalabrutinib Capsules, 100mg) was officially approved for marketing in China in March 2023. It is currently a prescription drug included in China’s Category B medical insurance.
Buy CALQUENCE (Acalabrutinib Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
